Please login to the form below
Chugai
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Chugai's Japan sales performance.
AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
Imfinzi in combination with chemotherapy (etoposide and either carboplatin or cisplatin) is approved in the first-line treatment of ES-SCLC in more than 55 countries, including the US, Japan, China
AbbVie signs gene therapy deal in eye care
Wet AMD – a significant cause of vision loss affecting up to two million people in the United States, Europe and Japan – is treatable with current anti-VEGF therapies but these require
CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
as we do in the US and Japan,” he added.
AstraZeneca clears latest hurdle for Alexion acquisition after EU clearance
The EU clearance comes after similar competition clearances in the US, Japan and other global regulatory agencies, AZ said in a statement.
AZ, HUTCHMED win first approval for MET inhibitor Orpathys in China
Japan’s medicines regulator.
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- EU “still interested” in Valneva COVID vaccine despite UK snub
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- US demand for COVID-19 antibody treatments rising fast
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- David Hunt launches independent agency The Considered
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- Live Webinar: Artificial Intelligence for Improving Patient Outcomes & Operational Efficiency
- CHANGING FACES: UNDERSTANDING THE KEY CUSTOMER CONTACT POINTS WITHIN THE ICS LANDSCAPE
- FDA approves Seagen/Genmab’s antibody-drug conjugate Tivdak for women with advanced cervical cancer
- AstraZeneca chooses Ireland for $360m manufacturing site
- Building the perfect behaviour-change buffet
- Live Webinar: Making Actionable Health Information More Accessible Through Point-of-Care Testing
- David Hunt launches independent agency The Considered
- Live Webinar: Making Actionable Health Information More Accessible Through Point-of-Care Testing
- Oxford PharmaGenesis wins Communiqué Medical Affairs Agency of the Year award at Communiqué 2021
- The transatlantic opioid crisis
- WHO to test three more potential COVID-19 treatments
- EU identifies first five ‘promising’ COVID-19 drugs as part of therapeutics strategy
PMHub
certain health
Transforming the way health brands and companies communicate, we deliver creative science led, insight-driven solutions that give award winning results...
Latest intelligence
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
